Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AORT
SELLArtivion, Inc. · Healthcare · United States · $1.2B · Avg Vol: $19M/d
COMPANY DESCRIPTION
Artivion, Inc. is a medical device company specializing in the development and manufacturing of innovative products for the surgical treatment of aortic diseases. The company offers a comprehensive portfolio including aortic grafts, stent grafts, and heart valve repair devices, serving a critical niche in cardiovascular surgery. Its competitive strength stems from its specialized expertise, strong clinical evidence, and established relationships within the global cardiac surgery community.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 313.8M | 354.0M | 388.5M | 441.3M | 12.0% | 458.7M | 486.2M | 539.7M | 10.6% |
| EPS | -0.38 | -0.48 | -0.75 | -0.32 | 0.22 | — | 0.25 | 0.15 | 0.25 | 6.9% |
| Shares | — | 40.3M | 41.1M | 41.9M | 47.8M | +18.6% | 48.5M | — | — | — |
| Debt | — | 356.8M | 358.3M | 362.3M | 257.6M | -10.3% | 258.2M | — | — | — |
| Equity | — | 284.3M | 281.8M | 276.2M | 448.2M | 16.4% | — | — | — | — |
| Op CF | — | -5.2M | 18.8M | 22.2M | 39.9M | 45.5% | 58.0M | — | — | — |
| Inv CF | — | -10.7M | -0.5M | -28.2M | -42.0M | — | — | — | — | — |
| Fin CF | — | -1.6M | 0.9M | 2.2M | 11.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AORT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AORT | Artivion, Inc.(you) | $1.2B | 22 | SELL |
| TNDM | Tandem Diabetes Care, Inc. | $1.2B | 25 | SELL |
| ATEC | Alphatec Holdings, Inc. | $1.3B | 27 | SELL |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.1B | 26 | SELL |
| BBNX | Beta Bionics, Inc. | $706M | 21 | SELL |
| PRCT | PROCEPT BioRobotics Corporation | $950M | 13 | STRONG SELL |
| CBLL | CeriBell, Inc. | $642M | 22 | SELL |
| ALMR | Alamar Biosciences, Inc. | $1.8B | 12 | STRONG SELL |
| BFLY | Butterfly Network, Inc. | $1.7B | 34 | SELL |
| IMR.AX | Imricor Medical Systems, Inc. | $455M | 16 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%